Latest News

CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma



According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.

Source link

Related posts

Medical News Today: What to know about femoral neuropathy

Newsemia

Opinion: Why we need mandatory labeling of GMO products

Newsemia

From clinic to courtroom, fighting for immigrant health care

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World